|
Heart failure
|
0.500 |
Biomarker
|
disease |
CTD_human |
Accordingly, antagonists of 5-HT(2B) receptors might represent novel therapeutics for sympathetic overstimulation-dependent heart failure.
|
19023134 |
2009 |
|
Congestive heart failure
|
0.500 |
Biomarker
|
disease |
CTD_human |
Finally, we demonstrate that 5-HT(2B) receptors are overexpressed in hearts from patients with congestive heart failure, this overexpression being positively correlated with cytokine and norepinephrine plasma levels.
|
19023134 |
2009 |
|
Heart valve disease
|
0.500 |
Therapeutic
|
group |
RGD |
Therefore, we sought to determine whether cyproheptadine, a 5-HT(2B)R antagonist, might prevent toxic valvulopathy in an animal model of pergolide-induced valvular heart disease.
|
19346455 |
2009 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT(2B) receptors on heart valves by the metabolite norfenfluramine.
|
19505264 |
2009 |
|
Heart failure
|
0.500 |
Biomarker
|
disease |
RGD |
Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle.
|
17936780 |
2007 |
|
Congestive heart failure
|
0.500 |
Biomarker
|
disease |
RGD |
Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle.
|
17936780 |
2007 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
[Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
|
16141947 |
2005 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
|
10617681 |
2000 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
Our data imply that activation of 5-HT(2B) receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT(2B) receptors are unlikely to produce VHD.
|
11104741 |
2000 |
|
Hypertensive disease
|
0.320 |
AlteredExpression
|
group |
BEFREE |
These data show that activation of 5-HT(2B) receptors is a limiting step in the development of pulmonary hypertension.
|
12244304 |
2002 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
BEFREE |
Also, the involvement of the 5-HT2B receptor in the vascular growth often observed in hypertension is likely.
|
11378296 |
2001 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
CTD_human |
The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats.
|
8627522 |
1996 |
|
Heart Failure, Right-Sided
|
0.310 |
Biomarker
|
disease |
BEFREE |
Furthermore, right ventricle-targeted therapies, aimed at mitigating the effects of functional right ventricular failure, include β-adrenoceptor (β-AR) blockers, angiotensin-converting enzyme (ACE) inhibitors, antioxidants, modulators of metabolism, and 5-hydroxytryptamine-2B (5-HT2B) receptor antagonists.
|
26583148 |
2015 |
|
Cardiomegaly
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Role of 5-HT 2B receptors in cardiomyocyte apoptosis in noradrenaline-induced cardiomyopathy in rats.
|
20374255 |
2010 |
|
Cardiomegaly
|
0.310 |
AlteredExpression
|
phenotype |
LHGDN |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Cardiomegaly
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Heart Failure, Right-Sided
|
0.310 |
Biomarker
|
disease |
CTD_human |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Cardiomegaly
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts.
|
15302781 |
2004 |
|
Cardiac Hypertrophy
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The 5-HT(2B) receptor antagonist SB 204741 partially reversed cardiac hypertrophy induced by NE overload (P < 0.05) and decreased L-type calcium currents in ventricular cardiomyocytes (P < 0.05).
|
20374255 |
2010 |
|
Left-Sided Heart Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Cardiac Hypertrophy
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Collectively, these results reveal for the first time that interactions between AT(1) and 5-HT(2B) receptors coexpressed by noncardiomyocytes are limiting key events in adrenergic agonist-induced, angiotensin-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Heart Decompensation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Drug toxicity
|
0.300 |
Biomarker
|
group |
CTD_human |
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
|
16863450 |
2005 |
|
Adverse reaction to drug
|
0.300 |
Biomarker
|
group |
CTD_human |
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
|
16863450 |
2005 |